Homepage Top Section2

The investment will be made in the Danish site of FUJIFILM Diosynth Biotechnologies with an aim to double the drug substance production capacity of the biologics production facility.

The US-Dutch collaboration will focus on advancing 47D11, a fully human, neutralising antibody therapeutic candidate. Discovery of the antibody was reported last month by Utrecht University, Erasmus Medical

According to Janssen, the subcutaneous formulation of daratumumab is administered as a fixed dose, which considerably brings down treatment time, from hours to nearly three to five minutes,

Remdesivir has been found to have provided significantly greater clinical improvement following its five-day treatment course, in comparison to treatment with standard of care alone, in the SIMPLE

The approval for the Tecentriq, Avastin combination is for unresectable or metastatic HCC patients who did not receive prior systemic therapy. Both the drugs, which already have approvals

The REMDACTA is a two-armed global phase III, randomised, double-blind and multicentre study designed to assess the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir against

As per the terms of the deal, Arcus Biosciences, which is a California-based oncology-focused biopharma company, will get a payment of $375m upon closing from Gilead Sciences. This

Themis Bioscience is said to have a pipeline of vaccine candidates and immune-modulatory therapies, which have been developed using its measles virus vector platform. In March 2020, the

In this connection, Novaremed has filed an investigational new drug (IND) application to the FDA. The clinical-stage Swiss biopharma company revealed to have got initial feedback from the